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Abstract
Purpose—Few studies have estimated population prevalence and morbidity of primary 
immunodeficiency diseases (PIDD). We used administrative healthcare databases to estimate the 
prevalence of PIDD diagnoses in the United States from 2001 to 2007.
Methods—MarketScan databases compile claims from commercial health insurance plans and 
Medicaid, recording individual diagnoses for outpatient encounters and hospital stays. We used a 
cross sectional survey to estimate prevalence of PIDD using related ICD-9 codes (279.0, 279.1, 
279.2, 279.8, 279.9, 288.1 and 288.2). Persons with secondary immunodeficiency diagnoses were 
excluded from analysis.
Results—Between 2001 and 2007, prevalence of any PIDD diagnosis increased from 38.9 to 
50.5 per 100,000 among privately insured and from 29.1 to 41.1 per 100,000 among publicly 
insured persons. B cell defects predominated. Prevalence was more than twice as high among 
Whites as among Blacks or Hispanics.
Conclusion—In this large database, we found a higher prevalence of diagnosed PIDD than has 
been reported previously from registries. Increased awareness may have contributed to the 
increasing prevalence.
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Primary Immunodeficiency diseases (PIDD) are a group of more than 130 distinct disorders 
caused by genetic defects of the immune system. Most of these disorders are caused by 
single gene defects, but the variable penetrance of these mutations results in heterogeneous 
phenotypes which leads to delays in diagnosis. Individuals with PIDD suffer from more 
frequent and severe infections and are likely to have frequent encounters with healthcare 
providers prior to a diagnosis of PIDD. Many patients continue to utilize healthcare 
resources at a higher rate than healthy individuals even after the diagnosis is made and 
treatment initiated [1].
PIDD are considered “rare” diseases, but most prevalence estimates have been based on 
selected populations (e.g. specialty clinics, disease registries). Disease registries from several 
countries suggest a prevalence of 1:8,500 to 1:100,000 persons [2–10]. Analysis of 
healthcare data from a single county in Minnesota estimated the incidence of PIDD to be 
10.3 per 100,000 person-years [11]. Data from a random telephone survey of 10,000 
households in the U.S. suggested a prevalence of 1:1200 persons [12].
Previous estimates have been based on disease registries or through reporting of specific 
PIDD in a clinical population [11, 13–19]. Extrapolating disease prevalence from the two 
U.S. studies, Bousfiha et al. calculated the estimated expected prevalence of PIDD cases and 
compared this to reported estimates in disease registries from the U.S., Europe, Asia and 
Australia. These estimated frequencies were much higher than the reported estimates based 
on the registry data suggesting both underreporting and ascertainment bias [20]. They 
concluded that the data obtained from registries does not provide adequate coverage to 
estimate prevalence or age distribution of PIDD.
In the United States, the development and implementation of newborn screening for severe 
combined immune deficiency (SCID) has begun to provide data on the birth prevalence of 
this combined immune deficiency [21–23].
The purpose of this study was to estimate the population prevalence of PIDD in a large 
national sample of children and adults using a cross sectional survey of data from 
commercial healthcare claims and Medicaid programs. Data on the number of 
hospitalizations and length of stay for persons with a PIDD diagnosis were available from 
the Commercial Claims and Encounters (CCE) for 2001 to 2007 and Multi-State Medicaid 
(MC) databases for 2001–2005. We also identified the most prevalent comorbidities 
associated with these hospitalizations. This is the first study to utilize data from a national 
population based database to estimate PIDD prevalence and hospitalizations.
Methods
Databases
Data were derived from the Truven Health MarketScan® 2001–2007 CCE and 2001–2005 
MC databases. These data included individual-level, de-identified enrollment data and health 
insurance claims across the continuum of care (both inpatient and outpatient). The CCE 
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database collects information from employers and health plans across the entire United 
States (37 contributors in 2001, 138 in 2007) who provide private healthcare coverage for 
enrollees and their dependents. Information was available for 5,816,905 enrollees in 2001 
increasing up to 28,761,500 enrollees in 2007, aged 64 years or younger. Individuals age 65 
and older were not included in the analysis since a large proportion of these persons receive 
their healthcare coverage through Medicare. The MC database included claims for pediatric 
patients (aged 0–21 years); it included 1,428,884 persons in 2001 increasing to 2,964,706 
persons in 2005. (Table 1) The MC database included 6 unidentified states in 2001 and 11 in 
2005. Both databases included demographic variables such as age and gender. Only the CCE 
database includes a variable specifying the geographic region of the United States for each 
enrollee and only the MC database includes a variable for race. Individual encounters 
included a unique enrollee identification number with the date of encounter, the site of 
service (inpatient, outpatient), the diagnosis code, the procedure codes, and information 
related to claims and payments. For hospital admissions, the length of stay and the diagnosis 
and procedure codes were recorded.
Inclusion/Exclusion Criteria
Only encounters with a valid unique identification number for each claim in the database 
were included in our analysis. The CCE and MC databases record outpatient and inpatient 
encounters, listing 2 ICD-9 codes for each outpatient encounter and up to 15 codes for 
hospitalizations. The International Classification of Disease, 9th Edition, Clinical 
Modifications (ICD-9) classifies PIDD according to the predominant immune defect (B cell 
defects, T cell defects, Combined defects, Neutrophil/Phagocyte defects, and Other 
nonspecified immune defects). The CCE and MC databases were queried for PIDD using 
these ICD-9 codes (Table 2). We excluded claims for persons who had any ICD-9 diagnosis 
code associated with secondary causes of immune deficiency, i.e. malignancies, infection 
with Human Immunodeficiency Virus (HIV) or treatment with immunosuppressive 
medications. (Table 2) We also excluded CCE enrollees age 65 years or older, who are 
covered by Medicare and less likely to participate in commercial insurance plans.
Statistical Methods
Data were extracted from MarketScan using Medstat DataProbe (Thomson Medstat, 2006) 
and analyzed using SAS version 9.2 (SAS Institute, Inc., Cary, NC). Data fields utilized in 
this analysis included age, gender, region (CCE only), race (MC only), ICD-9 diagnoses, 
type of encounter (outpatient, inpatient), and length of hospital stay. For CCE, age was 
stratified in the following groups 0–21, 22–34, 35– 44, 45–54 and 55–64 years. For 
comparisons of the pediatric populations, we created the following subgroups: <1, 1–5, 6–
10, 11–15 and 16–21 years of age.
Administrative prevalence (hereafter referred to as prevalence) for each year (2001–2007 for 
CCE; 2001–2005 for MC) was the number of persons with any PIDD diagnosis divided by 
the total enrolled population in a given year. Prevalence per 100,000 persons per year is 
shown in Table 3 by disease group (B cell defects, T cell defects, neutrophil defects, 
combined defects and other defects). Diagnosis groups were not mutually exclusive as one 
person could be counted in more than one group if they had one or more claim(s) with 
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ICD-9 codes from 2 or more different groups. All prevalence estimates were stratified by 
age, gender, race (MC only) and region (CCE only).
The proportion of persons with a hospital admission, the mean number of admissions per 
person and the mean length of stay were also calculated. The prevalence of comorbidities 
associated with hospital admissions (pathogen specific infections, respiratory infections, 
skin infections, chronic lung disease, and other nonspecific diagnoses associated with 
infections, such as fever, splenomegaly, bacteremia, weight loss) was estimated based on the 
frequency of these additional ICD-9 codes listed for each hospitalization (Table 2).
Tests for trend were used to evaluate changes in prevalence over time. For univariate 
analyses, chi square tests were used for categorical variables and nonparametric tests were 
employed where continuous data were not normally distributed. Linear and logistic 




The CCE database contained records from 5,816,905 enrollees in 2001 increasing to 
28,761,500 enrollees in 2007. The age, gender and regional distribution was similar to the 
U.S. population based on 2005 U.S. census data (Suppl. Table E1). The MC database 
contained information from 1,428,884 enrollees in 2001 increasing to 2,964,706 enrollees in 
2005. (Table 1) Persons who self-identified as “Black” were over represented in the MC 
population (34.6–39.2 %) compared to 12.3 % [24].
Population prevalence of any PIDD diagnosis increased 30 % from 38.9 to 50.5 per 100,000 
in CCE (p<0.0001) and 41 % from 28.2 to 39 per 100,000 in MC (p<0.0001). When 
stratified by diagnosis group, B cell defects accounted for most of the primary 
immunodeficiency diagnoses and also demonstrated the most marked increase in prevalence 
over time (p<0.0001 for CCE and MC). Both CCE and MC groups saw a significant increase 
in prevalence of T cell defects (p <0.0002) and Combined immune defects (p<0.01). The 
prevalence of neutrophil defects increased over time in the CCE population (p<0.0001), but 
not in the MC population. The prevalence of other defects increased over time in the MC 
population (p <0.0001) but not in the CCE population (Table 3).
When we stratified the CCE population by age, the older age groups (45–54, 55–64 years) 
had a higher prevalence for all PIDD diagnoses compared with the population aged 21 and 
younger. (Suppl. Table E2) In the pediatric population, the average prevalence of any PIDD 
was highest in the 1–5 years age group (CCE 46 to 67 per 100,000; MC 29 to 42 per 
100,000). For B cell defects, the average prevalence was highest in the 1–5 years range (MC 
20 to 25 per 100,000) and increased across all years (p<0.0001). In the MC population, the 
highest prevalence for T cell defects was observed among children <1 year of age (MC 15.6 
to 21.5 per 100,000) (Fig. 1).
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In the CCE population overall, females had a higher prevalence of any PIDD, B cell defects, 
neutrophil defects, combined immune defects and other immune defects. However, in both 
the CCE and MC pediatric populations, B and T cell defects were more common in males 
(results not shown). In the MC population the prevalence of combined immune defects (e.g. 
SCID) was highest in males (results not shown).
Information on race and ethnicity was available only for the MC database. To assess whether 
there were any racial disparities in the diagnosis of PIDD, we calculated the prevalence 
separately for Blacks (B), Whites (W) and Hispanics (H). The following results are based on 
2005 data; similar results were found for 2001–2004 (not shown). The prevalence of any 
PIDD among Whites was more than 2 times higher than among either Blacks or Hispanics 
(W=47.6 per 100,000, B=19.2, H=22.0). Whites also had higher prevalence than Blacks or 
Hispanic for B cell defects (25.9 per 100,000 versus 6.8 (B) or 1.3 (H)), T cell (11.0 per 
100,000 versus 4.2 (B) or 8.4 (H)), combined immune defects (3.6 versus 2.8 or 1.9) and 
other defects (7.2 versus 3.7 or 5.2) but not for neutrophil defects.
Associated Morbidity
We used information on number of hospital admissions and length of stay (LOS) to assess 
PIDD-associated morbidity. In the MC population the proportion of persons with a hospital 
admission was higher each year from 2001 to 2005 among those with PIDD (range 13.9 to 
18.6 %) compared to those without a PIDD diagnosis (range 7.9 to 8.9 %). Overall, persons 
with PIDD were about twice as likely to be hospitalized, controlling for year [Odds ratio 
1.916 to 2.260, p<0.0001]. In the CCE population persons with PIDD were slightly more 
likely to be hospitalized (OR 1.14, 95 % CI 1.094–1.189, p<0.0001). Having a PIDD 
diagnosis was also related to the mean number of admissions per person per year for the MC 
population (1.55 versus 1.16, p<0.0001).
Compared with the enrolled population as a whole, persons with a PIDD had significantly 
longer hospital stays (mean length of stay [LOS] per year). This was true for the CCE (all 
ages) [p<0.0001], CCE (0–21 years) and MC (p<0.0001) populations. LOS was significantly 
longer for children <1 year of age (CCE median=13.6 [range 8.8 to 22.3 days], MC 
median=21.1 [range 15.0 to 29.8 days]) than for those 1–21 years of age (CCE median=7.9 
[6.0 to 9.9 days], p<0.0001; MC mean=9.6 [7.4 to 11.4 days], p<0.0001)]. (Fig. 2 shows 
mean length of stay for 2005)
An increase in frequency and severity of infection is the hallmark of PIDD therefore, we 
examined the prevalence of a variety of comorbid diagnosis groups related to infections and 
the sequelae of infection associated with hospital admission for persons with any PIDD 
diagnosis. The ICD-9 diagnosis codes included those for pathogen specific infections, 
respiratory infections (e.g. pneumonia, sinus infections), skin infections, non-specific 
diagnoses associated with infection (e.g. fever, splenomegaly, bacteremia, weight loss), and 
diagnoses associated with sequelae of infection (e.g. chronic lung disease, chronic 
gastrointestinal disease). For both groups, non-specific infection associated comorbidities, 
respiratory infections, and pathogen specific infections had the highest prevalence among the 
comorbid conditions. Chronic lung disease also occurred commonly in both the MC and 
CCE populations. For each year (2001–2005), the prevalence of all infection related 
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comorbidities was higher in the MC population compared to the CCE population. The mean 
prevalence of each category of comorbidity over the years 2001–2007 for CCE and 2001–
2005 for MC is shown in Fig. 3.
Discussion
We used a national commercial claims database (CCE) and a sample of Medicaid data (MC) 
from multiple states to estimate the prevalence and morbidity of PIDD. Unlike previous 
estimates based on registry reports, our estimates are based on a very large geographically 
and racially diverse population.
Our prevalence estimates of 5.1:10,000 (CCE) and 3.9:10,000 (MC) for any PIDD are 
markedly higher than previous estimates from registries and two population surveys, which 
range from 1:10,000 to 1:100,000. Prevalence increased over time in both CCE and MC. B 
cell deficiencies accounted for roughly half of the cases, a proportion consistent with 
previously published reports [9, 13, 25]. Previous studies have suggested that low awareness 
of PIDD among physicians and the public contributes to delayed diagnosis [26–29]. Public 
awareness campaigns targeting both physicians and families can change behavior [30]. 
Campaigns conducted over the past decade to raise awareness of PIDD by educating 
physicians, other healthcare workers and the public could have contributed to the increase in 
prevalence seen in our study [18, 29, 31].
In the CCE population the prevalence of PIDD was highest among 55–64 years old with B 
cell defects accounting for 50 % in this group. Although PIDD are often considered pediatric 
diseases, the most common B cell defect, Common Variable Immune Deficiency (CVID), is 
often diagnosed in adults. The average age at diagnosis of CVID is 28–33 years of age [13, 
32]. In contrast, the prevalence of T cell defects in the CCE population was highest among 
persons 0–21 years of age (4–5 per 100,000); it was even higher in the MC population (6–10 
per 100,000), where the prevalence was highest in persons <1 year of age. T cell defects, 
which include disorders such as DiGeorge syndrome and immune dysregulation 
polyendocrinopathy enteropathy, X-linked (IPEX), cause severe clinical phenotypes, and are 
likely to present with symptoms at a young age.
In both the CCE and MC populations, 0–21 years of age, the prevalence of T cell defects and 
B cell defects was higher in males. In the MC population males had a higher prevalence of 
combined immune defects and neutrophil defects, as well as all PIDD. X-linked recessive 
inheritance accounts for about 50 % of cases of SCID in the U.S. [33], and is also the mode 
of inheritance of several other PIDD, including Bruton's agammaglobulinemia (XLA), X-
linked HyperIgM syndrome, Wiskott Aldrich syndrome, IPEX, NFκ β essential modifier 
(NEMO) and Chronic Granulomatous Disease. These disorders tend to have a severe clinical 
phenotype with symptoms manifesting in the first year of life.
It is more difficult to explain the higher prevalence of combined immune deficiency (ICD-9 
279.2) in persons age 55–64 years in the CCE population (2.1–3.2 per 100,000). ICD-9 
279.2 specifies combine immune deficiencies and typically is used for persons with 
congenital combined immune deficiencies such as SCID or thymic aplasia, not due to 
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DiGeorge syndrome. For the past 30 years combined immune defects (such as SCID) have 
been successfully treated using bone marrow or hematopoietic cell transplants [34–36]. 
However, persons over 30 years of age likely would not have benefitted from this advance in 
treatment. Other studies also identified large groups of adult patients. Among patients 
hospitalized in New York state between 2000 and 2004, Resnick et al. found that 34 % of 
patients with a PIDD diagnosis code were>45 years of age. Similar to our findings, 62/143 
of hospitalized persons with PIDD had a diagnosis of combined immune deficiency (279.2) 
[37].
Because ICD-9 codes 279.0, 279.1, and 279.8 used in our analysis are not specific for 
congenital immune defects, there may be some bias or misclassification. Although we 
attempted to remove persons with secondary immune deficiency due to HIV and 
malignancies from the analysis (Table 2), many persons with PIDD develop autoimmune 
disorders and malignancies and may be treated with drugs causing secondary immune 
defects. For these reasons, it was not possible to remove all subjects with underlying 
conditions causing immunosuppression.
The prevalence of any PIDD was more than twice as high in Whites as in Blacks or 
Hispanics, a pattern observed for all diagnosis groups, except neutrophil defects. Some 
genetically homogeneous populations have an increased prevalence of specific PIDD (e.g. 
Artemis SCID in Navajo Indians), but only a few registries have reported prevalence of 
specific PIDD (e.g. XLA, HyperIgM and CGD) by race [15–17]. In these reports, Whites 
comprise between 65 and 94 % of the patients. The only population based estimate of PIDD 
prevalence by race is from Olmstead county Minnesota, where 97 % of cases were in 
Whites; however this population is very homogeneous (90–95 % White) [11]. A possible 
explanation for our findings could be underdiagnoses among Black and Hispanic 
populations as a result of barriers to healthcare, or diagnostic bias. Several studies of PIDD 
diagnoses in urban clinical settings have reported under-representation of PIDD among 
minorities [15, 27, 38]. Further study is needed to identify possible impediments to 
diagnosis. The most accurate way to determine the population prevalence of a disorder is 
through population-wide screening. Recently published data from states performing 
newborn screening for Severe Combined Immune Deficiency have observed a birth 
prevalence of 1:50,000, which is two times higher than previous estimates [39, 40].
PIDD are chronic diseases and despite therapy with gamma globulin or prophylactic 
antibiotics, infections often continue to occur. Sequelae of infection, such as chronic lung 
disease, cause significant morbidity [41]. Our analysis demonstrated a significant increase in 
hospital admissions and length of stay for PIDD patients compared to the general 
population. Children <1 year had strikingly longer hospital stays than those 1–21 years of 
age. This could be explained by the fact that persons with PIDD with the most profound 
immune defects tend to present to the healthcare system earlier in life. Despite initiation of 
preventive therapy to reduce infections, persons with PIDD still experience significant 
infectious complications. We did not analyze the point of care for patients with PIDD, but it 
has been suggested that care in a specialized center may reduce hospitalizations and reduce 
health care costs [34].
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The most common comorbidities among hospitalized persons with PIDD included non-
specific infection associated comorbidities (fevers, splenomegaly, failure to thrive), 
respiratory infections, pathogen specific infections, and chronic lung disease. In the CCE 
and MC databases, we could assess the frequency of multiple comorbidities only for hospital 
encounters, since up to 15 ICD-9 codes were recorded only for inpatient encounters. The 
higher prevalence of acute infectious comorbidities among the MC population (0–21 years) 
may reflect the nature of presenting symptoms in younger children as well as their increased 
exposure to infectious illnesses. Assessment of pathogen specific infections was limited due 
to incomplete reporting.
Limitations
Our study utilized administrative claims data and without the benefit of medical chart 
review, we could not confirm PIDD diagnoses. In addition, only 4 digit ICD-9 codes were 
available for analysis reducing the specificity of disease classification. For example, ICD-9 
codes for diagnoses such as hypogammaglobulinemia (279.0), or other specified disorders of 
the immune system (279.9) do not specify whether these disorders are primary, or secondary. 
This makes it difficult to distinguish primary from secondary immune deficiencies using 
diagnostic ICD-9 codes alone. Although we attempted to exclude from analysis persons with 
secondary immune deficiencies (e.g. HIV infection, malignancies, organ transplants), this 
information was incomplete and could have resulted in misclassification of cases having a 
PIDD. Another limitation is that only two ICD-9 codes were reported for each outpatient 
encounter. In contrast, up to 15 codes were available for inpatient encounters. Thus, there 
could be under-ascertainment of cases for outpatient encounters if a code for PIDD was not 
included.
The databases we analyzed included all enrollees in the participating plans across each year. 
The CCE database does not include all commercial insurance plans and the MC database did 
not include all 50 states. In both CCE and MC databases persons may enter or be lost from 
year to year, depending on their insurance eligibility. To the extent that persons previously 
diagnosed with PIDD but did not have a PIDD-related claim in subsequent years, prevalence 
of PIDD in those years could be underestimated.
The CCE database's large size (more than 28,000,000 persons in 2007) and its similarity to 
the U.S. population with regard to gender and age distribution lend strength to our analysis 
and suggest that our findings could be generalizable to the U.S. population. However, we 
were not able to adequately assess the prevalence of PIDD in persons>65 years of age since 
only 0.1 % of the CCE population is in this age group. While gender and age distribution of 
the MC population mirrors the U.S. population as a whole, Blacks are over-represented. 
Although this limits the generalizability of the prevalence estimates, it also highlights the 
disparity in diagnosis of PIDD between Whites, Blacks and Hispanics 0–21 years of age.
Conclusion
This is the largest population-based study of PIDD prevalence to date, comprising almost 
10 % of the U.S. population. Our prevalence estimates are markedly higher than those 
previously reported from registries. We observed increasing prevalence of PIDD during the 
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study period. This trend could be due to increased awareness of PIDD among health care 
providers or the general population, but other factors such as increased availability of 
diagnostic testing could also play a role. Additional data is needed to determine if the lower 
prevalence of PIDD found among Black and Hispanic children on MC also exists in older 
populations and those with private insurance. Additional efforts should also attempt to 
elucidate the possible causes of this disparity.
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Table 1
Demographic characteristics of the Commercial Claims and Encounters (CCE) and Medicaid (MC) databases
Year 2001 2002 2003 2004 2005 2006 2007
Total enrollment CCE 5,816,905 7,656,625 7,699,763 13,136,933 17,560,383 16,159,068 28,761,500
MC 1,428,884 2,551,574 2,715,364 2,866,049 2,964,706 – –
Gender % CCE Female 52.0 52.4 52.6 51.8 51.8 51.5 51.3
CCE Male 48.0 47.6 47.4 48.2 48.2 48.5 48.7
MC Female 51.2 50.7 50.5 50.4 50.4 – –
MC Male 48.8 49.3 49.5 49.6 49.6 – –
Age groups CCE (yrs) 0–21 1,827,573 2,422,478 2,438,885 4,223,799 5,640,248 5,249,125 9,461,654
<1 102,396 146,847 151,994 261,465 363,999 331,883 599,846
1–5 329,041 460,400 465,682 823,040 1,120,266 1,042,244 1,879,157
6–10 390,070 516,975 517,496 910,407 1,224,565 1,143,177 2,072,231
11–15 446,342 583,778 590,564 1,031,672 1,370,225 1,274,871 2,252,706
16–21 559,724 714,478 713,049 1,197,215 1,561,193 1,456,950 2,657,714
22–34 934,999 1,300,506 1,310,389 2,367,229 3,252,262 2,904,017 5,298,314
35–44 987,971 1,281,577 1,289,363 2,242,456 3,027,094 2,746,752 4,851,016
45–54 1,157,208 1,457,178 1,443,143 2,398,147 3,170,155 2,942,310 5,190,915
55–64 909,154 1,194,886 1,217,983 1,905,302 2,470,624 2,316,864 3,959,601
Age groups MC (yrs) <1 115,569 183,977 185,844 196,110 204,352 – –
1–5 457,139 796,288 838,013 879,144 904,336 – –
6–10 345,914 615,412 647,135 677,298 702,220 – –
11–15 283,799 539,849 588,212 622,841 635,535 – –
16–21 226,463 416,048 456,160 490,656 518,263 – –
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Table 2
Inclusion and exclusion ICD-9 codes
Code description ICD-9 Codes
Inclusion
    B cell defects (e.g. hypogammaglobulinemia, CVID, XLA) 279.00–279.09
    T cell defects (e.g. DiGeorge syndrome, IPEX) 279.10–279.19
    Combined defects (e.g. SCID) 279.2
    Neutrophil defects (e.g. CGD, LAD, neutropenia) 288.1, 288.2
    Other specified disorders of the immune system (e.g. Complement deficiency, 279.8, 279.9
Exclusion
    HIV 042–044.9
    Malignancies (solid organs) 140–199
    Lymphoid tumors (e.g. multiple myeloma, hodgkins lymphoma) 200–203.8
    Chronic leukemias 204.1–207.8
    Metabolic disorders 260–273.9
    Transplants (kidney, heart, liver) V42.0–42.9
Comorbidities (hospitalizations)
    Infections with specific pathogens 001–136
    Organ specific infections: respiratory 461–488
    Organ specific infections: skin 680–686
    Chronic lung disease 490–496
    Chronic gastrointestinal disease 555–558
    Other comorbidities (fever, weight loss, splenomegaly, lymphadenopathy, bacteremia) 780.6, 783.2, 783.4, 785.6, 789.2, 790.7
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Table 3
Prevalence of primary immunodeficiency diseases (PIDD) per 100,000 enrolled persons by database and year
a. Commercial Claims and Encounters
2001 2002 2003 2004 2005 2006 2007
    All PID 38.9 40.8 41.2 42.0 43.2 48.4
50.5
*
    B cell 19.7 20.4 20.5 22.3 24.2 27.1
28.1
*
    T cell 2.9 2.8 2.5 2.6 3.0 2.7
3.4
*
    Combined 1.6 1.7 1.8 1.6 1.9 2.1 1.9
    Neutrophil 4.6 4.6 4.7 5.4 5.2 5.8
6.9
*
    Other 11.8 12.9 13.2 11.7 10.7 12.8 12.5
b Medicaid
    All PID 29.1 30.8 32.8 38.3
41.1
**
    B cell 15.5 13.9 13.9 18.4
18.9
**
    T cell 6.7 8.6 10.0 10.3
11.6
**
    Combined 1.5 2.0 1.9 2.2
3.8
**
    Neutrophil 3.4 3.0 3.3 3.7 3.5




Test for trend p<0.0002
**
Test for trend p<0.0001
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